CN103041069B - Pure Chinese medicinal composition for hyperlipidemia obesity and preparation method thereof - Google Patents
Pure Chinese medicinal composition for hyperlipidemia obesity and preparation method thereof Download PDFInfo
- Publication number
- CN103041069B CN103041069B CN201110408896.3A CN201110408896A CN103041069B CN 103041069 B CN103041069 B CN 103041069B CN 201110408896 A CN201110408896 A CN 201110408896A CN 103041069 B CN103041069 B CN 103041069B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- hyperlipidemia
- pure chinese
- obesity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 16
- 208000008589 Obesity Diseases 0.000 title claims abstract description 14
- 235000020824 obesity Nutrition 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 title claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 11
- 235000016425 Arthrospira platensis Nutrition 0.000 claims abstract description 9
- 240000002900 Arthrospira platensis Species 0.000 claims abstract description 9
- 229940082787 spirulina Drugs 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims description 18
- 241000756943 Codonopsis Species 0.000 claims description 8
- 241000222640 Polyporus Species 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- 239000012567 medical material Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 7
- 210000000952 spleen Anatomy 0.000 abstract description 2
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 241000222684 Grifola Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 9
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 231100000957 no side effect Toxicity 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a pure Chinese medicinal composition for hyperlipidemia obesity and a preparation method thereof. The composition comprises the following components in parts by weight: 100 parts of spirulina, 60 parts of baikal skullcap root, 120 parts of rhizoma alismatis, 60 parts of codonopsis pilosula, 60 parts of subprostrate sophora, 120 parts of grifola, 50 parts of folium sennae, and 50 parts of polygonum cuspidatum. The medicinal composition for hyperlipidemia obesity is a pure Chinese medicinal capsule, which can be used for soothing liver-qi stagnation, invigorating spleen and supplementing qi, removing stasis, reducing fat and losing weight and promoting fat metabolism by regulating body performance, so that the effect of treating hyperlipidemia and simple obesity can be achieved. The Chinese medicinal composition has the advantages of high safety, no toxic or side effect, no dependence, stable and controllable quality, simple preparation process and the like, is convenient for carrying and taking and can be produced by virtue of conventional equipment.
Description
Technical field
The invention belongs to medicine field, particularly relate to a kind of pure Chinese medicine combination for hyperlipidemia obesity and preparation method thereof.
Background technology
At present, a lot of about the product of blood fat reducing and fat-reducing on present market, but have effective, long-term taking safely, have no side effect, the product of no dependence is little.
Summary of the invention
Object of the present invention aims to provide a kind of pure Chinese medicine combination for hyperlipidemia obesity and preparation method thereof, it can overcome the shortcoming of existing market existing procucts, and have effective, safety is high, have no side effect, no dependence, stable and controllable for quality, be easy to carry and take, the simple advantage of preparation technology.
Technical scheme of the present invention is: provide a kind of pure Chinese medicine combination for hyperlipidemia obesity, it is characterized in that its crude drug composition and weight proportion thereof are: spirulina 100 parts, Radix Scutellariae 60 parts, Rhizoma Alismatis 120 parts, Radix Codonopsis 60 parts, Radix Sophorae Tonkinensis 60 parts, Polyporus 120 parts, Folium Sennae 50 parts, Rhizoma Polygoni Cuspidati 50 parts.
The preparation method of described a kind of pure Chinese medicine combination for hyperlipidemia obesity, is characterized in that it comprises the following steps:
1) by following weight ratio weighting raw materials: spirulina 100 parts, Radix Scutellariae 60 parts, Rhizoma Alismatis 120 parts, Radix Codonopsis 60 parts, Radix Sophorae Tonkinensis 60 parts, Polyporus 120 parts, Folium Sennae 50 parts, Rhizoma Polygoni Cuspidati 50 parts;
2) above-mentioned eight taste medical materials, get Radix Scutellariae, Rhizoma Alismatis, Rhizoma Polygoni Cuspidati are ground into fine powder respectively, cross 80 mesh sieves, for subsequent use;
3) Radix Codonopsis, Radix Sophorae Tonkinensis, Polyporus, Folium Sennae decoct with water twice, 2 hours first times, second time 1 hour, and collecting decoction filters, the filtrate obtained is concentrated into the clear paste of relative density 1.15-1.25;
4) fine powder that spirulina and step (2) sieved adds in the clear paste of step (3), 50 DEG C of drying under reduced pressure;
5) product step (4) obtained is pulverized, and crosses 40 mesh sieves; Upper capsule filling machine carries out filling;
6) inner packing;
7) outer package, product inspection, warehouse-in.
The capsule of the pure Chinese medicine combination in the present invention realizes dispersing the stagnated live-QI to relieve the stagnation of QI, invigorating the spleen and benefiting QI to regulate function of human body to reach, and dispel turbid long-pending, lowering blood-fat and reducing weight, promotes lipid metabolism, and then reaches the effect for the treatment of hyperlipidemia and simple obesity.
Advantage of the present invention is: Chinese medicine composition of the present invention have safety high, have no side effect, no dependence, stable and controllable for quality, be easy to carry and take, the advantage such as preparation technology is simple.
Detailed description of the invention
Below in conjunction with specific embodiment, the invention will be further described, but not as limitation of the present invention.The part do not described in detail in the present embodiment adopts prior art, and industry standard or known approaches.
?embodiment
Described pure Chinese medicine combination capsule adopts following steps to make:
1) raw material is taken by following weight ratio: spirulina 100 parts, Radix Scutellariae 60 parts, Rhizoma Alismatis 120 parts, Radix Codonopsis 60 parts, Radix Sophorae Tonkinensis 60 parts, Polyporus 120 parts, Folium Sennae 50 parts, Rhizoma Polygoni Cuspidati 50 parts;
2) above-mentioned eight taste medical materials, get Radix Scutellariae, Rhizoma Alismatis, Rhizoma Polygoni Cuspidati are ground into fine powder respectively, cross 80 mesh sieves, for subsequent use;
3) Radix Codonopsis, Radix Sophorae Tonkinensis, Polyporus, Folium Sennae decoct with water twice, 2 hours first times, second time 1 hour, collecting decoction, and filter, the filtrate obtained is concentrated into the clear paste of relative density (1.15-1.25);
4) fine powder that spirulina and step (2) sieved adds in the clear paste of step (3), mix homogeneously, 50 DEG C of drying under reduced pressure;
5) product step (4) obtained is pulverized, and crosses 40 mesh sieves; Upper capsule filling machine carries out filling;
6) inner packing;
7) outer package, product inspection, warehouse-in.
Here is the clinical observation of a kind of pure Chinese medicine combination capsule for treating hyperlipidemia for hyperlipidemia obesity of the embodiment of the present invention:
case selection
Except age person below 40 years old, suffer from outside the caused Secondary Hyperlipidemia such as diabetes, hypothyroidism, nephrotic syndrome, acute and chronic liver and gall diseases, all include research case in.Totally 160 examples, are divided into 2 groups at random, and treatment group takes embodiment of the present invention capsule 86 example, man 52 example, female 34 example, 61.50 years old mean age; Matched group 74 example, man 45 example, female 29 example, 62.80 years old mean age.Two groups of ages and the equal no significant difference of severity extent.
therapeutic Method
All cases measures TC, TG, HDL-C, LDL-C before administration on an empty stomach.The pure Chinese medicine combination capsule for hyperlipidemia obesity described in the oral inventive embodiments for the treatment of group, 0.9g/ grain, every day twice, the oral Simvastatin Tablets 20mg of matched group (20mg/ sheet), night every day decoction being taken at a draught, take 6 weeks all continuously for 2 groups, to stop using other fat-reducing medicament at viewing duration, after taking medicine, measure TC, TG, HDL-C, LDL-C on an empty stomach weekly.Treatments period should make regular check on blood fat, hepatic and renal function, cytometry, blood creatine phosphokinase.
result
From table 2, the forward and backward serum TC of 2 groups of patient treatments, TG, LDL-C all have obvious decline.Treatment group and matched group all obviously can raise HDL-C level, P<0.05 compared with before treatment.The effect for reducing blood fat showing 2 groups is suitable.But Chinese medicinal capsule involved in the present invention raises HDL-C horizon effect is better than matched group.
untoward reaction
2 groups of hepatic and renal functions, cytometry Non Apparent Abnormalities change, and treatment group has 4 routine blood creatine phosphokinases to raise, but without clinical symptoms.
This research, by the contrast with Simvastatin Treatment hyperlipemia curative effect, proves that Chinese medicinal capsule involved in the present invention reduces cholesterolemia and triglyceride, increases blood high density lipoprotein level obvious from curative effect.Serious adverse reaction is had no during clinical observation.Therefore think Chinese medicine combination of the present invention have safety high, have no side effect, no dependence, stable and controllable for quality, be easy to carry and take, the advantage such as preparation technology is simple, conventional equipment can complete production, is worth research further.
Claims (2)
1., for a pure Chinese medicine combination for hyperlipidemia obesity, it is characterized in that its crude drug composition and weight proportion thereof are: spirulina 100 parts, Radix Scutellariae 60 parts, Rhizoma Alismatis 120 parts, Radix Codonopsis 60 parts, Radix Sophorae Tonkinensis 60 parts, Polyporus 120 parts, Folium Sennae 50 parts, Rhizoma Polygoni Cuspidati 50 parts.
2. the preparation method of a kind of pure Chinese medicine combination for hyperlipidemia obesity according to claim 1, is characterized in that it is made up of following steps:
1) by following weight ratio weighting raw materials: spirulina 100 parts, Radix Scutellariae 60 parts, Rhizoma Alismatis 120 parts, Radix Codonopsis 60 parts, Radix Sophorae Tonkinensis 60 parts, Polyporus 120 parts, Folium Sennae 50 parts, Rhizoma Polygoni Cuspidati 50 parts;
2) above-mentioned eight taste medical materials, get Radix Scutellariae, Rhizoma Alismatis, Rhizoma Polygoni Cuspidati are ground into fine powder respectively, cross 80 mesh sieves, for subsequent use;
3) Radix Codonopsis, Radix Sophorae Tonkinensis, Polyporus, Folium Sennae decoct with water twice, 2 hours first times, second time 1 hour, and collecting decoction filters, the filtrate obtained is concentrated into the clear paste of relative density 1.15-1.25;
4) fine powder that spirulina and step (2) sieved adds in the clear paste of step (3), mix homogeneously, 50 DEG C of drying under reduced pressure;
5) product step (4) obtained is pulverized, and crosses 40 mesh sieves; Upper capsule filling machine carries out filling;
6) inner packing;
7) outer package, product inspection, warehouse-in.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110408896.3A CN103041069B (en) | 2011-12-11 | 2011-12-11 | Pure Chinese medicinal composition for hyperlipidemia obesity and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110408896.3A CN103041069B (en) | 2011-12-11 | 2011-12-11 | Pure Chinese medicinal composition for hyperlipidemia obesity and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103041069A CN103041069A (en) | 2013-04-17 |
| CN103041069B true CN103041069B (en) | 2014-12-17 |
Family
ID=48054080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110408896.3A Active CN103041069B (en) | 2011-12-11 | 2011-12-11 | Pure Chinese medicinal composition for hyperlipidemia obesity and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103041069B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105288498A (en) * | 2015-12-02 | 2016-02-03 | 青岛华之草医药科技有限公司 | Method for preparing folium artemisiae argyi-contained traditional Chinese medicine preparation capable of treating obesity |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103446571B (en) * | 2013-09-22 | 2015-06-03 | 曹丽荣 | Drug for dispelling dampness and losing weight |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101757598A (en) * | 2009-11-05 | 2010-06-30 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating advanced malignant liver tumor symptoms and preparation method thereof |
-
2011
- 2011-12-11 CN CN201110408896.3A patent/CN103041069B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101757598A (en) * | 2009-11-05 | 2010-06-30 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating advanced malignant liver tumor symptoms and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105288498A (en) * | 2015-12-02 | 2016-02-03 | 青岛华之草医药科技有限公司 | Method for preparing folium artemisiae argyi-contained traditional Chinese medicine preparation capable of treating obesity |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103041069A (en) | 2013-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102284005A (en) | Preparation method of sealwort and longan paste | |
| CN105105116A (en) | Health food with effects of relieving physical fatigue and enhancing immunity and preparation method of health food | |
| CN102283935A (en) | Preparation method of herba leonuri and longan paste | |
| CN103041069B (en) | Pure Chinese medicinal composition for hyperlipidemia obesity and preparation method thereof | |
| CN101940696B (en) | Method for preparing Chinese medicinal compound Zengshengping | |
| CN1054370A (en) | A kind of manufacture method of kidney-tonifying health-care medicament | |
| CN104288344B (en) | Application of Pu' er tea extract in preparation of medicine or food for regulating intestinal flora and relaxing bowels | |
| CN102640921A (en) | Dietary anti-aging tea granules | |
| CN101653507A (en) | Particle for relieving heat and cough | |
| CN103784918A (en) | Medicine composition for treating regurgitation-induced quidding of equus animals | |
| CN106309729B (en) | A kind of Chinese medicine composition adjusting chronic hepatitis immune function | |
| CN102640825A (en) | Lipid-lowering tea for regulating blood lipid | |
| CN104069144A (en) | Three formula granules for forming Shengmai powder and preparation method thereof | |
| CN102669344A (en) | Food senescence delaying tea granule | |
| CN108404088B (en) | Traditional Chinese medicine for treating type II diabetes and preparation method thereof | |
| CN107536921B (en) | Traditional Chinese medicine composition for treating hyperlipoproteinemia and application thereof | |
| CN104707106A (en) | Traditional Chinese medicine composition for treating fatty liver and preparation method thereof | |
| CN105125639A (en) | Traditional Chinese medicine composition for preventing and treating mastitis of dairy cattle | |
| CN105267722A (en) | Cough relieving and sputum removing Chinese patent medicine preparation and | |
| CN1682785A (en) | Liumotang preparation | |
| CN1334104A (en) | Hypolipemic pill | |
| CN104274800A (en) | Medicine for treating gastric diseases and preparation method thereof | |
| CN103356924A (en) | Drug for preventing and treating fatty liver and preparation method thereof | |
| CN102716448A (en) | Chinese patent medicine and TCM decoction capable of effectively curing nausea and vomiting | |
| CN1650916A (en) | Chinese medical preparation for treating fullness and pain in stomach duct and abdomen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Tang Yonghong Inventor after: Song Zhe Inventor after: Song Yuanzhi Inventor before: Song Yuanzhi Inventor before: Song Zhe Inventor before: Tang Yonghong |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: Room 1, No. 710077 B601 gazelle Valley in Shaanxi province high tech Zone of Xi'an Jinye Road No. 69 business development park C District Patentee after: XI'AN TAIKOMED MEDICAL TECHNOLOGY Co.,Ltd. Address before: 710077, 1-10502B, No. 2, No. 85, No. 3 Road, Xi'an hi tech Zone, Shaanxi Patentee before: Xi'an Takomed Pharmaceutical Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20240613 Address after: Room 1311, Building C, Chengfang Creation Century Plaza, No. 120 Yongwan Road, Xiuying District, Haikou City, Hainan Province, 570100 Patentee after: Jiayuan Pharmaceutical Investment (Hainan) Co.,Ltd. Country or region after: China Patentee after: Suzhou Guochen Enterprise Management Partnership (Limited Partnership) Address before: Room B601, gazelle Valley, No.1, Zone C, venture R & D Park, 69 Jinye Road, high tech Zone, Xi'an City, Shaanxi Province, 710077 Patentee before: XI'AN TAIKOMED MEDICAL TECHNOLOGY Co.,Ltd. Country or region before: China |